Monitoring Targeted Therapy Using Dual-energy CT: Semi-automatic RECIST Plus Supplementary Functional Information by Quantifying Iodine Uptake of Melanoma Metastases

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2013 Jul 24

PMID 23876444

Citations 15

Authors

M Uhrig

M Sedlmair

H P Schlemmer

J C Hassel

M Ganten

Affiliations

Soon will be listed here.

Abstract

Aim: Supplementary functional information can contribute to assess response in targeted therapies. The aim of this study was to evaluate semi-automatic RECIST plus iodine uptake (IU) determination in melanoma metastases under BRAF inhibitor (vemurafenib) therapy using dual-energy computed tomography (DECT).

Methods: Nine patients with stage IV melanoma treated with a BRAF inhibitor were included. Contrast-enhanced DECT was performed before and twice after treatment onset. Changes in tumor size were assessed according to RECIST. Quantification of IU (absolute value for total IU (mg) and volume-normalized IU (mg/ml)) was based on semi-automatic tumor volume segmentation. The decrease compared with baseline was calculated.

Results: The mean change of RECIST diameter sum per patient was -47% at the first follow-up (FU), -56% at the second FU (P < 0.01). The mean normalized IU per patient was -21% at the first FU (P < 0.2) and -45% at the second FU (P < 0.01). Total IU per patient, combining both normalized IU and volume, showed the most pronounced decrease: -89% at the first FU and -90% at the second FU (P < 0.01).

Conclusion: Semi-automatic RECIST plus IU quantification in DECT enables objective, easy and fast parameterization of tumor size and contrast medium uptake, thus providing 2 complementary pieces of information for response monitoring applicable in daily routine.

Citing Articles

Dual-energy computed tomography iodine uptake in differential diagnosis of inflammatory and malignant pulmonary nodules.

Qiu L, Pu X, Xu H, Yu T, Yuan M Diagn Interv Radiol. 2022; 28(6):563-568.

PMID: 36550756 PMC: 9885669. DOI: 10.5152/dir.2022.201091.

Prognostic role of iodine values for gastric cancer after neoadjuvant chemotherapy: a strong independent prognostic factor.

Zhang Y, Chen J, Yuan F, Zhang B, Ding B, Zhang H Diagn Interv Radiol. 2022; 28(5):388-395.

PMID: 35997476 PMC: 9682597. DOI: 10.5152/dir.2022.201007.

Quantitative dual-energy CT techniques in the abdomen.

Toia G, Mileto A, Wang C, Sahani D Abdom Radiol (NY). 2021; 47(9):3003-3018.

PMID: 34468796 DOI: 10.1007/s00261-021-03266-7.

Gastrointestinal Applications of Iodine Quantification Using Dual-Energy CT: A Systematic Review.

Xu J, Taudorf M, Ulriksen P, Achiam M, Resch T, Nielsen M Diagnostics (Basel). 2020; 10(10).

PMID: 33066281 PMC: 7602017. DOI: 10.3390/diagnostics10100814.

Dual-energy CT: theoretical principles and clinical applications.

Agostini A, Borgheresi A, Mari A, Floridi C, Bruno F, Carotti M Radiol Med. 2019; 124(12):1281-1295.

PMID: 31792703 DOI: 10.1007/s11547-019-01107-8.

References

Garbe C, Eigentler T, Keilholz U, Hauschild A, Kirkwood J . Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011; 16(1):5-24. PMC: 3228046. DOI: 10.1634/theoncologist.2010-0190. View

Zheng B, Jeong J, Asara J, Yuan Y, Granter S, Chin L . Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell. 2009; 33(2):237-47. PMC: 2715556. DOI: 10.1016/j.molcel.2008.12.026. View

Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J . Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16. PMC: 3549296. DOI: 10.1056/NEJMoa1103782. View

Joo I, Lee J, Kim K, Klotz E, Han J, Choi B . Liver metastases on quantitative color mapping of the arterial enhancement fraction from multiphasic CT scans: evaluation of the hemodynamic features and correlation with the chemotherapy response. Eur J Radiol. 2011; 80(3):e278-83. DOI: 10.1016/j.ejrad.2010.12.002. View

Guggenberger R, Gnannt R, Hodler J, Krauss B, Wanner G, Csuka E . Diagnostic performance of dual-energy CT for the detection of traumatic bone marrow lesions in the ankle: comparison with MR imaging. Radiology. 2012; 264(1):164-73. DOI: 10.1148/radiol.12112217. View

Wolchok J, Hoos A, ODay S, Weber J, Hamid O, Lebbe C . Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15(23):7412-20. DOI: 10.1158/1078-0432.CCR-09-1624. View

Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim P, Cho H . Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010; 467(7315):596-9. PMC: 2948082. DOI: 10.1038/nature09454. View

Hamer O, Biederer J, Das M, Kauczor H, Wielputz M, Ley-Zaporozhan J . [Comment on: Notification of revised diagnostic reference levels for diagnostic and interventional X-Ray Procedures by the Bundesamt für Strahlenschutz]. Rofo. 2022; 194(7):717-719. DOI: 10.1055/a-1813-3116. View

Flaherty K, Yasothan U, Kirkpatrick P . Vemurafenib. Nat Rev Drug Discov. 2011; 10(11):811-2. DOI: 10.1038/nrd3579. View

10.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

11.

Shanbhogue A, Karnad A, Prasad S . Tumor response evaluation in oncology: current update. J Comput Assist Tomogr. 2010; 34(4):479-84. DOI: 10.1097/RCT.0b013e3181db2670. View

12.

Lee S, Lee J, Kim K, Klotz E, Kim S, Lee J . Dual-energy computed tomography to assess tumor response to hepatic radiofrequency ablation: potential diagnostic value of virtual noncontrast images and iodine maps. Invest Radiol. 2010; 46(2):77-84. DOI: 10.1097/RLI.0b013e3181f23fcd. View

13.

Faivre S, Demetri G, Sargent W, Raymond E . Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007; 6(9):734-45. DOI: 10.1038/nrd2380. View

14.

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

15.

Esteve-Puig R, Canals F, Colome N, Merlino G, Recio J . Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS One. 2009; 4(3):e4771. PMC: 2651576. DOI: 10.1371/journal.pone.0004771. View

16.

Graser A, Johnson T, Chandarana H, Macari M . Dual energy CT: preliminary observations and potential clinical applications in the abdomen. Eur Radiol. 2008; 19(1):13-23. DOI: 10.1007/s00330-008-1122-7. View

17.

Graser A, Johnson T, Hecht E, Becker C, Leidecker C, Staehler M . Dual-energy CT in patients suspected of having renal masses: can virtual nonenhanced images replace true nonenhanced images?. Radiology. 2009; 252(2):433-40. DOI: 10.1148/radiol.2522080557. View

18.

Figueiras R, Padhani A, Goh V, Vilanova J, Gonzalez S, Villalba Martin C . Novel oncologic drugs: what they do and how they affect images. Radiographics. 2011; 31(7):2059-91. DOI: 10.1148/rg.317115108. View

19.

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

20.

Chandarana H, Megibow A, Cohen B, Srinivasan R, Kim D, Leidecker C . Iodine quantification with dual-energy CT: phantom study and preliminary experience with renal masses. AJR Am J Roentgenol. 2011; 196(6):W693-700. DOI: 10.2214/AJR.10.5541. View